and RADFs (GFR MG: 4.4 fold, MG: 4.8 fold) to GFR MG was observed compared to MG.

Discussion According to present knowledge and in comparison to results obtained from RASFs, SSCDFs do not show the ability to migrate from their application site to internal organs. Adhesive properties do not differ from healthy controls. Nevertheless, SSCDFs are mediators of organ fibrosis, but it seems that there is no contribution of SSCDFs to the spreading of the disease.

**Background and Objectives**

SSc is a prototypic multorgan disease characterised by vascular damage, autoimmunity and fibrosis with still unknown aetiology. Recently identified functional autoantibodies simultaneously targeting the angiotensin-II type-1 receptor (AT1R-Abs) and the endothelin-1 receptor type A (ETAR-Abs) were linked to vascular and fibrotic complications in SSC. Presence of both autoantibodies moreover predicted mortality due to cardiopulmonary complications implicating their contribution in SSC pathogenesis. Here, autoantibody mediated effects on endothelial cell activation and their blockade by receptor inhibitors were studied.

**Materials and Methods**

Human microdermal endothelial cells-1 (HMEC-1) and human dermal fibroblasts were treated with IgG from SSC patients containing anti-AT1R and anti-ETAR Abs (SSc-IgG) or with IgG from healthy donors (NC-IgG) as negative control. In parallel, SSc-IgG treated cells were incubated with AT1R- and ETAR- antagonists alone and in combination. Activation of endothelial cells was assessed by qRT-PCR and sandwich ELISA and of fibroblasts with immunocytochemistry.

**Results**

Human endothelial cells showed increased expression and production of the pro-inflammatory chemokine interleukin-8 (IL-8) upon treatment with SSc-IgG positive for anti-AT1R and anti-ETAR Abs compared to control treatment with NC-IgG as analysed on mRNA and on protein levels. Furthermore, endothelial cells showed increased expression of the adhesion molecules vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) with SSc-IgG versus NC-IgG treatment on mRNA levels. Expression of IL-8 and VCAM-1 was significantly decreased by receptor inhibition. Human dermal fibroblasts showed increased collagen 1 production upon treatment with SSc-IgG versus NC-IgG that was also reduced by receptor inhibition.

**Conclusions**

Our data suggests a direct involvement of anti-AT1R and anti-ETAR Abs in endothelial cell and fibroblasts activation that is mediated by AT1R and ETAR activation. Increased expression of IL-8 and of VCAM-1 and ICAM-1 indicate a direct endothelial cell activation and inflammation. Increased collagen 1 production indicates fibroblast activation and pro-fibrotic events. Therefore, anti-AT1R and anti-ETAR Abs induce pro-inflammatory and pro-fibrotic events and could be directly involved in the pathogenesis of SSc. In vivo experiments are underway to analyse anti-AT1R and anti-ETAR Abs mediated pathogenic events in SSc.

**Background and Objectives**

Arthritis in idiopathic inflammatory myopathies (IIM) is frequently observed in clinical practise, but, to our knowledge, there is lack of systemic reports of prevalence and/or characteristics of arthritis in myositis patients. The aim of this study is to determine prevalence of arthritis in IIM patients; its relation to the course of the muscle disease; characteristics of arthritis with respect to seriousness, distribution and extent as well as its relation to autoantibody profiles and others disease’s characteristics.

**Materials and Methods**

In this cross-sectional study, clinical aspects of disease, history of arthritis and autoantibody profiles were obtained from 106 consecutive patients with definite diagnosis of IIM. In all of them the 68-joint index was investigated. In 55 IIM patients and in 60 control patients with rheumatoid arthritis (RA) German Ultrasound Score 7 (US-7) was performed.

**Results**

Arthritis at any time of course of myositis occurred in 65 patients (61.3%); 42 had arthritis at the beginning of myositis (in 22 patients before and in 16 together with onset of muscle weakness), 52 patients presented arthritis at clinical examination (25 poly-, 17 oligo-, and 10 with monoarthritis). Most frequently affected joints were wrists (21.7%) and shoulders, metacarpophalangeal, and proximal interphalangeal joints (20.8%). From 29 anti-jo-1 positive patients 28 had arthritis and significant association between arthritis and anti-jo-1 positivity was found (p < 0.0001). 39 out of 55 (70.9%) patients had Gray-Scale (GS) synovitis on ultrasound; in 34 of them also Power-Doppler (PD) positivity was found. Only 4 patients had ultrasonographic tenosynovitis and 3 bony erosions. From 60 RA patients 57 (95%) had GS synovitis, which was PD-active in 54. Tenosynovitis was found in 25 patients. 25 RA patients had one or more joint erosions. Mean US-7 score as well as scores of individual joints or modality subscres were significantly lower in IIM than in RA, but, when compared only those patients with positive findings, the differences were found in total US-7 score, and GS-synovitis and PD-tenosynovitis subscres, but not in PD-synovitis, GS-tenosynovitis as well as in scores of individual joints.

**Conclusions**

Our data suggest that arthritis is common feature of myositis. It is often present at the beginning of muscular manifestation of disease, or it even precedes the onset of muscle weakness. Most common presentation is symmetrical, non erosive polyarthitis affecting particularly wrists, shoulders, metacarpophalangeal and proximal interphalangeal joints of the hands. We confirmed strong association of arthritis with anti-Jo-1 antibody. Ultrasound investigation of joint involvement in IIM shows less frequent involvement than in RA, but, comparable activity of synovitis measured by PD in affected joints. IIMs have less erosions and tenosynovitis than RA.